Affymax prepares to mount first challenge to Amgen anemia drug monopoly 1/25/2012 Tweet Email a Friend Print Article Affymax is making moves behind the scenes that will determine how big a bite it will take out of Amgen’s multi-billion dollar anemia drug monopoly, Xconomy reports. CLICK HERE TO READ MORE MORE IN RENAL BUSINESS Tweet Email a Friend Print Article